| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14737140.2018.1413939 |
| P698 | PubMed publication ID | 29210294 |
| P50 | author | Richard G Gorlick | Q56427012 |
| P2093 | author name string | David S Geller | |
| Valerae O Lewis | |||
| Douglas J Harrison | |||
| Jonathan D Gill | |||
| P2860 | cites work | A comparative study between limb-salvage and amputation for treating osteosarcoma | Q26753095 |
| Osteosarcoma: Current Treatment and a Collaborative Pathway to Success | Q26797555 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R | Q30357731 | ||
| Compress knee arthroplasty has 80% 10-year survivorship and novel forms of bone failure | Q30534456 | ||
| Intensive Induction Chemotherapy without Methotrexate in Adult Patients with Localized Osteosarcoma: Results of the Institut Gustave-Roussy Phase II Trial | Q33393253 | ||
| Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program | Q33406382 | ||
| Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. | Q33419286 | ||
| Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. | Q33434899 | ||
| Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways | Q33582914 | ||
| Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features | Q33753959 | ||
| Cemented distal femoral endoprostheses for musculoskeletal tumor: improved survival of modular versus custom implants | Q33956306 | ||
| Osteosarcoma treatment - where do we stand? A state of the art review. | Q34392457 | ||
| Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. | Q34404179 | ||
| Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. | Q34413741 | ||
| Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. | Q34532932 | ||
| Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy | Q39340821 | ||
| Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. | Q40166492 | ||
| Primary Osteosarcoma of Bone: A Clinicopathologic Investigation of 243 Cases, with Necropsy Studies in 54 | Q40484531 | ||
| Retrospective evaluation of the incidence of early periprosthetic infection with silver-treated endoprostheses in high-risk patients: case-control study | Q41517963 | ||
| Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. | Q41613919 | ||
| Computer-assisted surgery in orthopedic oncology | Q41887178 | ||
| Surgical technique: Computer-generated custom jigs improve accuracy of wide resection of bone tumors | Q41904238 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin | Q42556370 | ||
| Surgical guides (patient-specific instruments) for pediatric tibial bone sarcoma resection and allograft reconstruction | Q43223770 | ||
| Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? | Q44202173 | ||
| Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis | Q47667534 | ||
| Navigated pelvic osteotomy and tumor resection: a study assessing the accuracy and reproducibility of resection planes in Sawbones and cadavers | Q48690737 | ||
| CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 pha | Q50481939 | ||
| The use of massive bone allograft with intramedullary free fibular flap for limb salvage in a pediatric and adolescent population | Q51154694 | ||
| Segmental femur reconstruction using an intercalary allograft with an intramedullary vascularized fibula bone flap | Q51688208 | ||
| Can computer navigation-assisted surgery reduce the risk of an intralesional margin and reduce the rate of local recurrence in patients with a tumour of the pelvis or sacrum? | Q53093915 | ||
| Skeletal reconstruction with a free vascularized fibula graft associated to bone allograft after resection of malignant bone tumor of limbs | Q53887029 | ||
| Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution | Q56994814 | ||
| RANKL expression is related to treatment outcome of patients with localized, high‐grade osteosarcoma | Q57226639 | ||
| Use of a patient-specific CAD/CAM surgical jig in extremity bone tumor resection and custom prosthetic reconstruction | Q58493680 | ||
| International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons | Q34605959 | ||
| A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study | Q34628840 | ||
| Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group | Q34743615 | ||
| Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma | Q35030373 | ||
| What was the survival of megaprostheses in lower limb reconstructions after tumor resections? | Q35050283 | ||
| Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma | Q35624496 | ||
| Biology and therapeutic advances for pediatric osteosarcoma | Q35841976 | ||
| Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward | Q36072962 | ||
| Germline TP53 variants and susceptibility to osteosarcoma. | Q36294747 | ||
| Survival trends and long-term toxicity in pediatric patients with osteosarcoma. | Q36440294 | ||
| Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial | Q36503647 | ||
| Haptic robot-assisted surgery improves accuracy of wide resection of bone tumors: a pilot study | Q36585992 | ||
| Future directions in the treatment of osteosarcoma. | Q36600800 | ||
| Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. | Q36653789 | ||
| A review of clinical and molecular prognostic factors in osteosarcoma | Q36983787 | ||
| Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma | Q37125088 | ||
| Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program | Q37295112 | ||
| Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group | Q37439345 | ||
| Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. | Q37471124 | ||
| Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. | Q37545590 | ||
| Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy | Q37575208 | ||
| Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. | Q37624276 | ||
| The role of interferons in the treatment of osteosarcoma | Q37630430 | ||
| Osteosarcoma: review of the past, impact on the future. The American experience | Q37705055 | ||
| Osteosarcoma: the COSS experience | Q37705062 | ||
| Palliative therapy for osteosarcoma. | Q37845831 | ||
| Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? | Q37894250 | ||
| Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma | Q38219831 | ||
| Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma | Q38219845 | ||
| Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial | Q38870980 | ||
| Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. | Q38902256 | ||
| Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2. | Q38932369 | ||
| A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes | Q39086751 | ||
| The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli | Q39240570 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 39-50 | |
| P577 | publication date | 2017-12-14 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Review of Anticancer Therapy | Q2999044 |
| P1476 | title | Current and future therapeutic approaches for osteosarcoma | |
| P478 | volume | 18 |
| Q103831973 | A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing |
| Q58773880 | A novel circulating hsa_circ_0081001 act as a potential biomarker for diagnosis and prognosis of osteosarcoma |
| Q90310234 | A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma |
| Q91675874 | Adult Stem Cells for Bone Regeneration and Repair |
| Q98159042 | Ailanthone: A novel potential drug for treating human cancer |
| Q98289244 | Analysis of changes in the expression of Notch1 and HES1 and the prognosis of osteosarcoma patients following surgery |
| Q64087780 | Anti-cancer targets of formononetin and molecular mechanisms in osteosarcoma: Findings of bioinformatic and experimental assays |
| Q95643038 | Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling |
| Q64296784 | Bone transport using the Ilizarov method for osteosarcoma patients with tumor resection and neoadjuvant chemotherapy |
| Q90330859 | CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis |
| Q98291685 | Circular RNA circHIPK3 Promotes Cell Metastasis through miR-637/STAT3 Axis in Osteosarcoma |
| Q60938885 | Clinical outcomes of patients with primary malignant bone and soft tissue tumor aged 65 years or older |
| Q90222934 | Curative-intent radiotherapy for pediatric osteosarcoma: The St. Jude experience |
| Q90720288 | Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma |
| Q55279130 | Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis. |
| Q92340181 | Degradation of long non-coding RNA-CIR decelerates proliferation, invasion and migration, but promotes apoptosis of osteosarcoma cells |
| Q98178384 | Development of Natural-Based Bone Cement for a Controlled Doxorubicin-Drug Release |
| Q91634112 | Down-regulation of LINC00472 promotes osteosarcoma tumorigenesis by reducing FOXO1 expressions via miR-300 |
| Q92408428 | Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma |
| Q64963698 | Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study. |
| Q64256698 | Efficacy of methotrexate, doxorubicin, and cisplatin for osteosarcoma: Study protocol for a systematic review of randomized controlled trial |
| Q59356084 | Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors |
| Q92969709 | Evaluating and Predicting the Probability of Death in Patients with Non-Metastatic Osteosarcoma: A Population-Based Study |
| Q58712167 | Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway |
| Q91750003 | Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group |
| Q99619235 | Flavonoid compound breviscapine suppresses human osteosarcoma Saos-2 progression property and induces apoptosis by regulating mitochondria-dependent pathway |
| Q57287602 | GAPLINC is a predictor of poor prognosis and regulates cell migration and invasion in osteosarcoma |
| Q92114751 | Ganoderma lucidum Exerts an Anticancer Effect on Human Osteosarcoma Cells via Suppressing the Wnt/β-Catenin Signaling Pathway |
| Q90219601 | Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma |
| Q64963105 | Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. |
| Q64104434 | Improving Magnetofection of Magnetic Polyethylenimine Nanoparticles into MG-63 Osteoblasts Using a Novel Uniform Magnetic Field |
| Q92835393 | Influence mechanism of miRNA-144 on proliferation and apoptosis of osteosarcoma cells |
| Q57028266 | Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells |
| Q64275790 | Innovative Biomaterials for Bone Regrowth |
| Q89495814 | Interleukin-22 modulates cisplatin sensitivity of osteosarcoma cells by regulating the STAT3 signaling pathway |
| Q101052571 | Knockdown of CircCRIM1 Inhibits HDAC4 to Impede Osteosarcoma Proliferation, Migration, and Invasion and Facilitate Autophagy by Targeting miR-432-5p |
| Q93182898 | LINC00514 drives osteosarcoma progression through sponging microRNA-708 and consequently increases URGCP expression |
| Q64077526 | LOXL1-AS1 predicts poor prognosis and promotes cell proliferation, migration, and invasion in osteosarcoma |
| Q64967835 | LSINCT5 predicts unfavorable prognosis and exerts oncogenic function in osteosarcoma. |
| Q90435514 | LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis |
| Q90447953 | Long non-coding RNA LINC00152 promotes tumorigenesis via sponging miR-193b-3p in osteosarcoma |
| Q61806369 | Low-dose eribulin reduces lung metastasis of osteosarcoma and |
| Q91896797 | Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells via Reactive Oxygen Species-Mediated Apoptosis and Autophagy |
| Q57494127 | MiR-1281, a p53-responsive microRNA, impairs the survival of human osteosarcoma cells upon ER stress via targeting USP39 |
| Q89739864 | MicroRNA-320a inhibits invasion and metastasis in osteosarcoma by targeting cytoplasmic polyadenylation element-binding protein 1 |
| Q64083375 | Non‑covalent proteasome inhibitor PI‑1840 induces apoptosis and autophagy in osteosarcoma cells |
| Q64261018 | PDCD5 inhibits osteosarcoma cell metastasis via targeting TGF-β1/Smad signaling pathway and is associated with good prognosis |
| Q90616566 | PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1 |
| Q94526125 | Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway |
| Q90250223 | Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma |
| Q92711420 | Prediction of Chemotherapy Response of Osteosarcoma Using Baseline 18F-FDG Textural Features Machine Learning Approaches with PCA |
| Q90136493 | Predictors of the Survival of Primary and Secondary Older Osteosarcoma Patients |
| Q93200198 | Prognostic Significance of β-Catenin Expression in Osteosarcoma: A Meta-Analysis |
| Q58572917 | Progress in the chemotherapeutic treatment of osteosarcoma |
| Q64121884 | Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study |
| Q91789542 | Sevoflurane Inhibited Osteosarcoma Cell Proliferation And Invasion Via Targeting miR-203/WNT2B/Wnt/β-Catenin Axis |
| Q89793844 | Strontium/Chitosan/Hydroxyapatite/Norcantharidin Composite That Inhibits Osteosarcoma and Promotes Osteogenesis In Vitro |
| Q60919990 | Targeting the Wnt/β-catenin pathway in human osteosarcoma cells |
| Q89699693 | The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis |
| Q57043971 | Von Willebrand factor rescued by miR-24 inhibition facilitates the proliferation and migration of osteosarcoma cells in vitro |
| Q60054218 | WNT6 is an effective marker for osteosarcoma diagnosis and prognosis |
| Q64376975 | [Twist regulates proliferation, migration and invasion of osteosarcoma cells in vitro] |
| Q89939825 | circPVT1 Facilitates Invasion and Metastasis by Regulating miR-205-5p/c-FLIP Axis in Osteosarcoma |
| Q92748597 | miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma |
| Q92855999 | miR-495-3p inhibits the cell proliferation, invasion and migration of osteosarcoma by targeting C1q/TNF-related protein 3 |
| Q93165768 | β-Phenethyl Isothiocyanate Induces Cell Death in Human Osteosarcoma through Altering Iron Metabolism, Disturbing the Redox Balance, and Activating the MAPK Signaling Pathway |
Search more.